Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.

Ionis Pharmaceuticals announced that Roche, the company’s partner firm, is designing a new Phase II trial that would assess the effectiveness of tominersen in younger adult patients diagnosed with Huntington’s disease. 

One week after expanding the company’s neurodegenerative diseases partnership with Bristol Myers Squibb, Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.

Merck & Co. Inc. and partner Ridgeback Biotherapeutics LP said on January 18 they had signed an agreement with the United Nations Children’s Fund (UNICEF) to supply up to 3 million courses of their COVID-19 antiviral pill.

Building on Novo Nordisk’s success during June 2021 in obtaining the first drug approval for weight management since 2014, the Danish pharma giant is partnering with biotech company EraCal Therapeutics to develop new obesity-related drug targets. 

Scorpion Therapeutics and AstraZeneca partnered to develop precision medicines against previously hard-to-target cancer proteins.

Syneos Health released the biopharmaceutical solutions organization’s 12th annual Dealmakers’ Intentions Survey. Conducted on an annual basis, the survey provides a review of biopharmaceutical dealmakers’ expectations for deal activity, supply and demand for specific assets in different development stages, pitfalls leading to deal failure and other factors affecting dealmaking.

California-based Dren Bio and Pfizer partnered on a deal valued at more than $1 billion to discover and develop therapeutic bispecific antibodies for select oncology targets.

The COVID-19 pandemic has brought to light the incredible power of collaboration in the life science industry. About 40 percent of Pfizer’s portfolio was realized through partnerships, and the pharma giant announced three more collaborative deals on January 10.

Vancouver, Wash.-based Absci Corporation inked a research pact with Merck. Absci will leverage the company’s Bionic Protein non-standard amino acid technology and its artificial intelligence-powered integrated Drug Creation Platform to create enzymes to meet Merck’s biomanufacturing applications.